Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 Monotherapy in ART-Naïve HIV-1
NCT05494736Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA), Number of Participants Experiencing ≥1 Adverse Event (AE) at 28 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05494736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494736.